Centessa Pharmaceuticals plc
CNTA
$39.59
-$0.02-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 118.88% | 118.88% | 118.88% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 118.88% | 118.88% | 118.88% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 118.88% | 118.88% | 118.88% | -- |
| SG&A Expenses | -0.68% | 1.54% | 3.10% | -2.76% | -5.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.76% | 35.78% | 36.41% | 27.45% | 12.87% |
| Operating Income | -3.30% | -32.26% | -32.78% | -23.50% | -17.38% |
| Income Before Tax | 15.97% | -51.15% | -43.52% | -34.47% | -32.23% |
| Income Tax Expenses | -36.04% | 15.42% | 872.78% | 114.89% | 111.35% |
| Earnings from Continuing Operations | 16.21% | -50.50% | -46.41% | -61.72% | -56.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 16.21% | -50.50% | -46.41% | -61.72% | -56.04% |
| EBIT | -3.30% | -32.26% | -32.78% | -23.50% | -17.38% |
| EBITDA | -3.34% | -32.45% | -32.85% | -23.41% | -17.13% |
| EPS Basic | 27.24% | -19.82% | -14.46% | -27.31% | -26.63% |
| Normalized Basic EPS | 15.82% | -4.58% | 2.66% | 7.32% | 4.72% |
| EPS Diluted | 27.24% | -19.82% | -14.46% | -27.31% | -26.63% |
| Normalized Diluted EPS | 15.82% | -4.58% | 2.66% | 7.32% | 4.72% |
| Average Basic Shares Outstanding | 18.61% | 25.82% | 27.50% | 25.98% | 18.98% |
| Average Diluted Shares Outstanding | 18.61% | 25.82% | 27.50% | 25.98% | 18.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |